Yeah read the Seeking Alpha article. Its missing a few key points for mine.....
Namely the capital raise in August and the indications off a tripling of patient numbers by year end.....definitely changes his revenue multiple to a much more reasonable number if the company guidance is to be taken at face value. The problem is there has been no further guidance on monitoring numbers from the company to give clarity around revenue moving forward.
So the company has stated that they will do 3x last years patient number of 27946. 27946 x 3 = 83,838 patients CY2020.
Numbers i get for the year and to reach that projection are as follows:
So this gives revenue of ~ USD 16,142,000 per annum, at a market cap of USD332mio at IPO - which gives a Rev to Market cap multiple of 20.....which is much more palatable
GMV Price at posting:
3.9¢ Sentiment: Buy Disclosure: Held
